Arizona Alzheimer's Disease Research Center (ADRC)

June 2, 2022 updated by: Banner Health
The Arizona Alzheimer's Disease Research Center (ADRC) is the National Institute on Aging's (NIA's) first statewide AD Center (ADC), the only ADC in the Southwestern United States, and a leading example of statewide collaboration in biomedical research. It capitalizes on Arizona's strengths in brain imaging, genomics, computer science and biomathematics, the basic, cognitive and behavioral neurosciences, clinical, and neuropathological studies of AD, the discovery and evaluation of investigational treatments, and the study of normal cognitive aging.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Anticipated)

550

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The Clinical Core maintains a target of 550 participants at all stages of the aging-dementia spectrum including 400 normal controls and 150 participants with MCI, probable AD dementia and other dementias. Embedded within these diagnostic categories are defined Latino and Native American cohorts.

Participants will be referred to the ADRC from varying sources including, but not limited to, clinic referrals, community outreach programs, general advertising, national registries, and other sites within the consortium.

Participants eligible for enrollment and those completing annual follow-up are discussed in frequent diagnostic consensus conferences. All undergo a standardized neuropsychological and neurological battery of tests at entry and annual tests at all sites.

Description

Inclusion Criteria:

  • Cognitively normal persons, individuals with mild cognitive impairment or dementia who are at least 40 years of age.
  • Willing to undergo health and cognitive assessments, and collection and banking of blood with venipuncture for genetic research, biomarker research, and DNA banking.

Exclusion Criteria:

  • 1. Participants whose diagnosis is unclear and confounded by multiple possible factors are excluded. Participants with diagnoses of non-AD dementias are not excluded.

    2. Participants whose primary diagnosis is cognitive impairment due to a penetrating or single severe closed head injury, multiple sclerosis, brain tumor, metabolic or toxic encephalopathy, post-infectious (e.g., viral encephalitis, bacterial meningitis), paraneoplastic, primary psychiatric illness, or otherwise not deemed relevant to the intent of the Alzheimer Disease Center program are excluded.

    3. Procedure specific exclusion criteria also apply but this does not impact the participants ability to be included in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognitive Status
Time Frame: 12 months
The ADRC uses a prospective, standardized, and longitudinal clinical evaluation of participants to determine their cognitive status. This includes tests that assess short and long term memory, ability to complete daily tasks, and processing of information.
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Banner Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2021

Primary Completion (Anticipated)

June 30, 2026

Study Completion (Anticipated)

June 30, 2026

Study Registration Dates

First Submitted

March 4, 2022

First Submitted That Met QC Criteria

June 2, 2022

First Posted (Actual)

June 6, 2022

Study Record Updates

Last Update Posted (Actual)

June 6, 2022

Last Update Submitted That Met QC Criteria

June 2, 2022

Last Verified

June 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ADRC-001

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alzheimer Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe